Cargando…

The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer

IMPORTANCE: Gemcitabine-nab-paclitaxel (GEMNAB) and fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) both improve survival of patients with advanced pancreatic cancer when compared with single-agent gemcitabine in clinical trials. OBJECTIVE: To describe changes in the survival of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raphael, Michael J., Raskin, William, Habbous, Steven, Tai, Xiaochen, Beca, Jaclyn, Dai, Wei F., Arias, Jessica, Forbes, Leta, Gavura, Scott, Biagi, James J., Earle, Craig C., Chan, Kelvin K. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593760/ https://www.ncbi.nlm.nih.gov/pubmed/34779846 http://dx.doi.org/10.1001/jamanetworkopen.2021.33388

Ejemplares similares

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
por: Arciero, Vanessa, et al.
Publicado: (2022)

Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada
por: Habbous, Steven, et al.
Publicado: (2022)

Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario
por: Naipaul, Rohini D., et al.
Publicado: (2021)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer?
por: Dai, Wei Fang, et al.
Publicado: (2019)

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
por: Chan, Kelvin, et al.
Publicado: (2020)

Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
por: Chan, Kelvin K. W., et al.
Publicado: (2019)

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
por: Dai, Wei Fang, et al.
Publicado: (2020)

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
por: Pataky, Reka E., et al.
Publicado: (2021)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Variation in Practice Patterns and Reimbursements Between Female and Male Urologists for Medicare Beneficiaries
por: Nam, Catherine S., et al.
Publicado: (2019)

Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
por: Herbrand, Amanda Katherina, et al.
Publicado: (2021)

Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study
por: Beca, Jaclyn M., et al.
Publicado: (2021)

Screening and discrimination of optimal prognostic genes for pancreatic cancer based on a prognostic prediction model
por: Chen, Zhiqin, et al.
Publicado: (2021)

Concordance of Disclosed Hospital Prices With Total Reimbursements for Hospital-Based Care Among Commercially Insured Patients in the US
por: Horný, Michal, et al.
Publicado: (2021)

Immediate Postpartum Long-Acting Reversible Contraceptive Use Following State-Specific Changes in Hospital Medicaid Reimbursement
por: Steenland, Maria W., et al.
Publicado: (2022)

Association of the Swiss Diagnosis-Related Group Reimbursement System With Length of Stay, Mortality, and Readmission Rates in Hospitalized Adult Patients
por: Kutz, Alexander, et al.
Publicado: (2019)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Variation in Diagnosis, Treatment, and Outcome of Esophageal Cancer in a Regionalized Care System in Ontario, Canada
por: Habbous, Steven, et al.
Publicado: (2021)

Adolescent Access to Federally Funded Clinics Providing Confidential Family Planning Following Changes to Title X Funding Regulations
por: Krass, Polina, et al.
Publicado: (2022)

Assessment of US Federal Funding of Incarceration-Related Research, 1985 to 2022
por: Boch, Samantha J., et al.
Publicado: (2023)

National Institutes of Health Funding Gaps for Principal Investigators
por: Gillen, Kelly M., et al.
Publicado: (2023)

Delivery of Cancer Care in Ontario, Canada, During the First Year of the COVID-19 Pandemic
por: Walker, Meghan J., et al.
Publicado: (2022)

Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study
por: Habbous, Steven, et al.
Publicado: (2020)

Examining the association between oncology drug clinical benefit and the time to public reimbursement
por: Thomson, Sasha, et al.
Publicado: (2021)

Dental safety net providers’ experiences with service delivery during the first year of COVID-19 should inform dental pandemic preparedness
por: Raskin, Sarah E., et al.
Publicado: (2022)

Reimbursement for Durable Medical Equipment
por: Janssen, Theodore J., et al.
Publicado: (1981)

An Analysis of the Effects of Prospective Reimbursement Programs On Hospital Expenditures
por: Coelen, Craig, et al.
Publicado: (1981)

Association of Brain Metastases With Survival in Patients With Limited or Stable Extracranial Disease: A Systematic Review and Meta-analysis
por: Li, Alyssa Y., et al.
Publicado: (2023)

Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations
por: Jenei, Kristina, et al.
Publicado: (2023)

Reimbursement of Bus Fares
Publicado: (1954)

The History of Reimbursements in Neurology
por: Lakhan, Shaheen E., et al.
Publicado: (2013)

Introduction: Pharmacy Reimbursement
por: Greenwood, Bonnie C.
Publicado: (2020)

Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019
por: Ballreich, Jeromie M., et al.
Publicado: (2021)

Association Between COVID-19 Relief Funds and Hospital Characteristics in the US
por: Cantor, Jonathan, et al.
Publicado: (2021)

Federal Funding and Citation Metrics of US Biomedical Researchers, 1996 to 2022
por: Ioannidis, John P. A., et al.
Publicado: (2022)

Analysis by Gender and Race and Ethnicity of Reviewers and Awardees for Intramural Research Funding in the Veterans Health Administration
por: Boyer, Taylor L., et al.
Publicado: (2023)

Association of Funding and Meal Preparation Time With Nutritional Quality of Meals of Supplemental Nutritional Assistance Program Recipients
por: Olfat, Matt, et al.
Publicado: (2021)

How is Clinical Trial Reimbursement Money Spent? South African Trial Participants’ Reported Reimbursement Spending Patterns and Perceptions of Appropriate Reimbursement Amounts
por: Milford, Cecilia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q36kh773iatqkdc8lc4qeq2tin